TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent prior to any study specific procedures~* Healthy male volunteers aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venepuncture~* Have a body mass index (BMI) between 19 and 30 kg/m2 and a body weight between 60 and 100 kg~* Be a non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for more than 3 months prior to the start of the study~Exclusion Criteria:~* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study~* Any clinically significant abnormalities in physical examination, clinical chemistry, haematology or urinalysis results as judged by the Investigator~* Abnormal vital signs, after 10 minutes supine rest, defined as any of the following: Systolic blood pressure (SBP) greater than 140 mmHg, Diastolic blood pressure (DBP) greater than 90 mmHg, Heart rate less than 40 or greater than 85 beats per minute - at Visit 1~* Prolonged QTcF \>450 ms or shortened QTcF \<340 ms~* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This includes volunteers with any of the following: Clinically significant PR (PQ) interval prolongation, Intermittent second or third degree AV block (Mobitz II type 1, Wenchebach during sleep is not disqualifying), Incomplete, full or intermittent bundle branch block (QRS less than 110 ms with normal QRS and T wave morphology is acceptable if there is no evidence of left ventricular hypertrophy), Abnormal T wave morphology, particularly in the protocol defined primary lead

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CXL104 (Type: EXPERIMENTAL): 2000 mg NXL104 + 1500 mg Ceftaroline (IV)
- CAZ104 (Type: EXPERIMENTAL): Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin 400mg (1 tablet)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Infusion (saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 Years to 65 Years ASA I and II Accepts healthy volunteers.~Exclusion Criteria:~alcohol or illicit drugs, H2 inhibitors, opioids, or calcium-channel blockers within the last 10 days chronic pain, myocardial ischemia, psychiatric diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- S(+)-ketamine group (SG) (Type: ACTIVE_COMPARATOR): Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
- placebo group (PG) (Type: PLACEBO_COMPARATOR): PG received the same dose of saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unresectable complex hilar cholangiocarcinoma which diagnosis and staging based on computed tomography(CT) or magnetic resonance cholangiopancreatography (MRCP)~Exclusion Criteria:~* Patients with ASA 4 or 5~* Patients with liver failure.~* Patients unable to comply with follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEMS (Type: EXPERIMENTAL): self-expandable metal stent group
- PS (Type: ACTIVE_COMPARATOR): plastic stent group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sugar Champ: Pilot Social Network Intervention to Reduce Intake of Sugary Drinks

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* BMI≥25 kg/m2~* Must consume sugar-sweetened beverages at least twice daily~* Peer Educators must identify one high-risk alter in the social network to enroll as Sidekick~* Resides in select public housing developments in Baltimore, MD~Exclusion Criteria:~* Any underlying medical conditions that could seriously reduce life expectancy, ability to participate in the trial, or for which lifestyle change may be contraindicated and/or require medical supervision by a physician such as medication-dependent diabetes mellitus, cancer, lung disease requiring supplemental oxygen, dementia, angina, or diagnosis in the last 12 months of myocardial infarction, transient ischemic attack or stroke~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Social network intervention (Type: EXPERIMENTAL): Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 6 months to 17 years 11 months of age, inclusive;~* Female subjects of childbearing potential must use adequate contraception~* Diagnosed with CDAD~Exclusion Criteria:~* Concurrent use of oral vancomycin or metronidazole or any other effective treatments for CDAD~* Fulminant colitis~* History of inflammatory bowel disease~* Pregnant or breast-feeding~* Need for concurrent use of some P-glycoprotein inhibitors during therapy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- fidaxomicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BT200 in Hereditary Bleeding Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:To be eligible for this study, patients must meet all of the following inclusion criteria:~1. Hereditary bleeding disorder:~   * Congenital hemophilia A without inhibitors with a prophylactic treatment regime~  * Heterozygous carriers of hemophilia A with subnormal FVIII levels~  * VWD Type 1, Vicenza type~  * VWD Type 2b~2. Male or female, age ≥18-70 years old at Screening~3. If female, must be post-menopausal or surgically sterilized~4. Able to comprehend and to give informed consent~5. Able to cooperate with the Investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related procedures -~Exclusion Criteria: Patients meeting any of the following criteria will be excluded from the study:~1. Clinically significant medical history or ongoing chronic illness that would jeopardize the safety of the patient or compromise the quality of the data derived from his/her participation in this study~2. Medical History of spontaneous (not FVIII or FEIBA-associated) venous or arterial thromboembolic events~3. History of significant drug allergy or anaphylactic reactions~4. Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the Investigator for the patient to be able to comply fully with study procedures~5. Use of medication during 2 weeks before the start of the study, which in the judgment of the Investigator may adversely affect the patient's welfare or the integrity of the study's results~6. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5 elimination half-lives (whichever is longer) prior to treatment start -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Subcutaneous (SC) injection:~BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ≥18 years of age with histologically confirmed at initial diagnosis, previously treated (at least 2 prior chemotherapy regimens), low-grade NHL or low-grade lymphoma that had transformed to intermediate- or high-grade histology.~Exclusion Criteria:~* Subjects with more than an average of 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry. Bilateral posterior iliac crest core biopsies are required if the percentage of intratrebecular space involved exceeds 10% in a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.~* Cytotoxic chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment within 4 weeks prior to study entry or persistent clinical evidence of toxicity.~* Prior stem cell transplant.~* Active obstructive hydronephrosis.~* Evidence of active infection requiring intravenous (IV) antibiotics at the time of study entry.~* New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation.~* Prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the subject has been disease-free for 5 years.~* Known HIV infection.~* Known brain or leptomeningeal metastases.~* Subjects who are pregnant or nursing.~* Previous allergic reactions to iodine. This does not include reactions to intravenous iodine-containing contrast materials.~* Prior exposure to monoclonal or polyclonal antibodies of any non-human species for either diagnostic or therapeutic purposes, including engineered chimeric and humanized antibodies.~* Prior radioimmunotherapy.~* Progressive disease within 1 year of irradiation arising in a field that has been previously irradiated with \>3500 cGy.~* Current use of either approved or non-approved (through another protocol) anti-cancer drugs or biologics~* De novo intermediate- or high-grade lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- open-label single arm (Type: EXPERIMENTAL): Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of mantle cell lymphoma (MCL)~  * Expression of cyclin D1 or evidence of t(11;14) translocation by cytogenetics, FISH, or polymerase chain reaction~* Refractory to or relapsed or progressed after first line antineoplastic therapy~* Measurable disease~PATIENT CHARACTERISTICS:~Inclusion criteria:~* Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2~* ANC ≥ 1,000/mm³ (not related to lymphoma)~* Platelet count ≥ 30,000/mm³~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Total bilirubin ≤ 2 times ULN~* Creatinine clearance ≥ 20 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Known serological positivity for HBV, HCV, or HIV~* History of allergic reaction attributable to compounds containing boron or mannitol~* Diagnosed or treated for a malignancy other than MCL within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or any in situ malignancy~* Active systemic infection requiring treatment~* Serious medical or psychiatric illness that would preclude study participation~PRIOR CONCURRENT THERAPY:~Inclusion criteria:~* Toxic effects of prior therapy or surgery must be resolved to ≤ grade 2~* Prior splenectomy or localized radiotherapy allowed~* Any prior chemotherapy regimen allowed~  * Chemotherapy may have been given in combination with rituximab~* Concurrent enrollment in a nontreatment study allowed, provided it does not interfere with participation in this study~Exclusion criteria:~* Prior bortezomib~* Antineoplastic therapy within the past 3 weeks~* Nitrosoureas within the past 6 weeks~* Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody within the past 4 weeks~* Radiotherapy within the past 3 weeks~* Major surgery within the past 2 weeks~* Concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib plus CHOP (Type: EXPERIMENTAL): Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Incretins on Human Platelet Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy blood donors~Exclusion Criteria:~* Diabetes~* Hypertension~* Morbid obesity~* Cardiovascular disease~* Hematological diseases and hyperlipidemia

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- controls (Type: None): Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe aortic stenosis~* Coronary artery disease associated with poor left ventricular function~* Parsonnet score \>7~Exclusion Criteria:~* Dementia or inability to understand the study protocol~* Off-pump and emergent cardiac surgery~* Poorly controlled diabetes mellitus~* Severe renal insufficiency~* Abnormal liver function Child-Plugh - C~* Body Mass Index \< 18 and \> 35

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Administration of glucose-insulin-potassium
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 19 to 45 inclusive~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ \[height (m)\]2~Exclusion Criteria:~* Women of child-bearing potential (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product~* Any significant acute or chronic medical illness~* Current or recent (within 3 months) gastrointestinal disease~* Any major surgery within 4 weeks of study drug administration~* History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds~* History of allergy or intolerance to metformin or other similar acting agents~* Prior exposure to saxagliptin~* Prior exposure to metformin within 3 months of study drug administration~* Estimated creatinine clearance (Clcr) of \< 80ml/min using the Cockcroft Gault formula

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Type: OTHER): Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
- Arm B (Type: OTHER): Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
- Arm C (Type: OTHER): Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
- Arm D (Type: OTHER): Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients at least 18 years of age with moderate to severe active RA for at least 6 months;~* inadequate response to current anti-rheumatic therapies, including 1 or more traditional DMARDs;~* stable DMARD therapy for at least 8 weeks before entering study;~* patients of reproductive potential must be using reliable methods of contraception.~Exclusion Criteria:~* major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study;~* patients who have previously failed treatment with an anti-tumor necrosis factor agent;~* women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete